Drug
Conivaptan clinical trials
Also written Vaprisol and YM087.
- studies test it
- 21
- open now
- 0
- in phase 3
- 7
- first study started
- 2000
How studies write it
Studies that test it under each name
Studies by the year they started
21 studies that test it; most in 2009 (6)
| Year | Studies |
|---|---|
| 2000 | 2 |
| 2002 | 1 |
| 2004 | 1 |
| 2007 | 3 |
| 2008 | 3 |
| 2009 | 6 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2015 | 1 |
| 2017 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 3
- Phase 3
- 7
- Phase 4
- 4
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 9
Cumberland Pharmaceuticals (12) · Jesse Corry (1) · Finn Gustafsson (1) · University of Washington (1) · Northwestern University (1) · Hennepin County Medical Center, Minneapolis (1) · University of Florida (1) · Columbia University (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses conivaptan is read from its arms, and is right about nine times in ten.
Testing it · 21
- Use of Conivaptan (Vaprisol) for Hyponatremic Neuro-ICU PatientsTerminatedPhase 4Northwestern UniversityNCT00727090Written as Conivaptan
- Conivaptan for the Reduction of Cerebral Edema in Intracerebral Hemorrhage- A Safety and Tolerability StudyCompletedPhase 1Jesse CorryNCT03000283Written as Conivaptan
- Study of Stroke Related Edema TreatmentsWithdrawnPhase 2University of FloridaNCT01954290Written as Conivaptan
- A Study to Assess the Efficacy, Safety and Pharmacokinetics of Intravenous Conivaptan (Vaprisol®) in Pediatric Subjects With Euvolemic or Hypervolemic HyponatremiaTerminatedPhase 3Cumberland PharmaceuticalsNCT01451411Written as Conivaptan hydrochloride
- Effects on Exercise Hemodynamics of Vasopressin Blockade by Conivaptan Infusion in Heart Failure PatientsCompletedPhase 4Finn GustafssonNCT01752543Written as Conivaptan
- Safety and Efficacy of Conivaptan for the Correction of Hyponatremia in Neurological PatientsWithdrawnPhase 3Columbia UniversityNCT00684164Written as Conivaptan
- A Study of Multiple Dosing Regimens of IV Conivaptan in Subjects With Euvolemic or Hypervolemic HyponatremiaCompletedPhase 4Cumberland PharmaceuticalsNCT00435591Written as Conivaptan
- Study of Efficacy & Safety for 3 Infusion Regimens of IV Conivaptan in Subjects With Euvolemic or Hypervolemic HyponatremiaCompletedPhase 3Cumberland PharmaceuticalsNCT00478192Written as Conivaptan
- A Study to Assess the Safety and Effects of Intravenous (IV) Conivaptan on the Hepatic Hemodynamic Response in Cirrhotic PatientsCompletedPhase 2Cumberland PharmaceuticalsNCT00592475Written as conivaptan
- Safety and Efficacy of Conivaptan in Hyponatremic Patients With Symptomatic Acute Decompensated Heart Failure (ADHF)TerminatedPhase 3Cumberland PharmaceuticalsNCT00843986Written as conivaptan
- Study to Compare Conivaptan in Subjects With Mild & Moderate Liver Impairment Versus Subjects With Normal Liver FunctionCompletedPhase 1Cumberland PharmaceuticalsNCT00851227Written as conivaptan hydrochloride
- Study to Compare Conivaptan Pharmacokinetics in Subjects With Mild & Moderate Kidney Function Impairment to Subjects With Normal Kidney FunctionCompletedPhase 1Cumberland PharmaceuticalsNCT00887627Written as conivaptan hydrochloride
- A Study to Assess the Effect of Severe Hepatic Impairment on the Pharmacokinetics of Intravenous ConivaptanCompletedPhase 1Cumberland PharmaceuticalsNCT01370148Written as conivaptan hydrochloride
- Study of IV YM087 to Assess Efficacy and Safety in Patients With Euvolemic or Hypervolemic HyponatremiaCompletedPhase 3Cumberland PharmaceuticalsNCT00380575Written as YM087
- Study of Efficacy & Safety of Oral YM087 in Subjects With Euvolemic or Hypervolemic HyponatremiaCompletedPhase 3Cumberland PharmaceuticalsNCT00492037Written as YM087 oral
- Safety and Efficacy Study of YM087 (Conivaptan) in Patients With Acute Decompensated Heart FailureCompletedPhase 2Cumberland PharmaceuticalsNCT00057356Written as conivaptan
- An Open-Label Study of YM087 (Conivaptan) in Patients With Euvolemic or Hypervolemic HyponatremiaCompletedPhase 3Cumberland PharmaceuticalsNCT00379847Written as conivaptan
- Body Volume Regulation in Pulmonary Arterial Hypertension With Right Ventricular FailureWithdrawnNot applicableUniversity of Colorado, DenverNCT00811486Written as Spironolactone and conivaptan
- Diuretic and Renal Effects of Vaprisol When Administered Along With Furosemide and Nesiritide Continuous InfusionWithdrawnPhase 4Albert Einstein Healthcare NetworkNCT00806910Written as Conivaptan
- Study of the Safety and Efficacy of Conivaptan (Vaprisol®) to Raise Serum Sodium Levels in Patients With Severe Traumatic Brain InjuryCompletedPhase 1University of WashingtonNCT00930202Written as Conivaptan (Vaprisol)
Codes
What other systems call conivaptan · ClinicalTrials.gg INT003985
- MeSH (NLM) C106389conivaptanConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 0NJ98Y462XCONIVAPTANConfirmed FDA, NLM, Wikidata
- RxNorm 302285Confirmed FDA, Wikidata
- Wikidata Q5161126conivaptanConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C74428ConivaptanOne source FDA
- DrugBank DB00872One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C106389 | conivaptan | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 0NJ98Y462X | CONIVAPTAN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 302285 | — | Confirmed FDA, Wikidata |
| Wikidata | Q5161126 | conivaptan | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C74428 | Conivaptan | One source FDA |
| DrugBank | DB00872 | — | One source Wikidata |
Also registered as conivaptan hydrochloride (UNII 75L57R6X36 · RxNorm 1294548).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.